Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by losingmyshirton Sep 18, 2020 3:36pm
164 Views
Post# 31582909

Future bleaker than ever

Future bleaker than ever

1 year Kalytera Therapeutics Forecast: 0.000000 USD *

Alert! Please note that this asset seems fundamentally flawed meaning that we can't recommend investing it. This could be for various reasons: abandoned by the developers, faulty code, intentionally malicious project, etc.

As of 2020 September 18, Friday current price of KALTF stock is 0.000100$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).

Kalytera Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period.

Our site uses a custom algorithm based on Deep Learning that helps our users to decide if KALTF could be a bad portfolio addition. These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks.

Future price of the stock is predicted at 0.000000$ (-100.000% ) after a year according to our prediction system.

This means that if you invested $100 now, your current investment may be worth 0$ on 2021 September 18, Saturday.

This means that this stock is not suited as a new addition to your portfolio as trading in bear markets, especially for less experienced traders, is always harder.

<< Previous
Bullboard Posts
Next >>